ALX Oncology (ALXO) Stock Price, News & Analysis

Company Overview

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing therapies that activate the immune system to fight cancer. The company’s approach targets the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid being identified and destroyed by macrophages and other immune cells.

ALX Oncology’s lead product candidate is evorpacept, formerly known as ALX148. Evorpacept is an investigational fusion protein designed to block the CD47 “don’t eat me” signal while limiting the binding of normal blood cells. The company has evaluated evorpacept in combination with other cancer treatments, including antibody therapies, across multiple solid-tumor and hematologic cancer settings.

The company’s clinical development programs have included studies in head and neck cancer, gastric and gastroesophageal-junction cancer, and other oncology indications. ALX Oncology is headquartered in South San Francisco, California, and has pursued clinical development through collaborations and trials involving research centers and patients in the United States and other regions. As a clinical-stage biotechnology company, its products remain investigational and are not approved for commercial use.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $1.31 to $2.11
• 52-Week Range: $1.05 to $2.66
• Volume: 1.17 million shs
• Average Volume: 975,919 shs
• Market Capitalization: $181.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.60
• Consensus Rating: Moderate Buy

ALX Oncology Stock Analysis - MarketRank™

ALX Oncology scored higher than 56% of companies evaluated by MarketBeat, and ranked 433rd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ALX Oncology has a consensus price target of $4.60, representing about 251.1% upside from its current price of $1.31.

Amount of Analyst Coverage

ALX Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ALX Oncology are expected to decrease in the coming year, from ($0.60) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ALX Oncology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ALX Oncology is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ALX Oncology has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.18% of the float of ALX Oncology has been sold short.

Short Interest Ratio / Days to Cover

ALX Oncology has a short interest ratio ("days to cover") of 7.79.

Change versus previous month

Short interest in ALX Oncology has recently decreased by 11.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ALX Oncology does not currently pay a dividend.

Dividend Growth

ALX Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.11

News Sentiment

ALX Oncology has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ALX Oncology this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,274.00 in company stock.

Percentage Held by Insiders

12.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALXO
• CIK: 1810182
• Web: www.alxoncology.com
• Phone: 650-466-7125
• Fax: N/A
• Employees: 48
• Year Founded: 2015

Price Target and Rating

• Average Price Target for ALX Oncology: $4.60
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +251.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.30%
• Return on Assets: -67.28%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 9.71
• Quick Ratio: 9.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 138,280,000
• Free Float: 121,131,000
• Market Cap: $181.15 million
• Optionable: Optionable
• Beta: 0.39